Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol

BACKGROUND: All current approved antipsychotic drugs against schizophrenia spectrum disorders share affinity for the dopamine receptor (D2R). However, up to one-third of these patients respond insufficiently, and in some cases, side-effects outweigh symptom reduction. Previous data have suggested th...

Descripción completa

Detalles Bibliográficos
Autores principales: Baltzersen, Olga B., Meltzer, Herbert Y., Frokjaer, Vibe G., Raghava, Jayachandra M., Baandrup, Lone, Fagerlund, Birgitte, Larsson, Henrik B.W., Fibiger, H. Christian, Glenthøj, Birte Y., Knudsen, Gitte M., Ebdrup, Bjørn H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204912/
https://www.ncbi.nlm.nih.gov/pubmed/32425802
http://dx.doi.org/10.3389/fphar.2020.00591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204912/
https://www.ncbi.nlm.nih.gov/pubmed/32425802
http://dx.doi.org/10.3389/fphar.2020.00591

Ejemplares similares